Research Analysts Set Expectations for ESPR FY2026 Earnings

by · The Cerbat Gem

Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) – HC Wainwright lifted their FY2026 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a research note issued to investors on Thursday, November 6th. HC Wainwright analyst J. Pantginis now forecasts that the biopharmaceutical company will post earnings per share of $0.40 for the year, up from their previous forecast of $0.35. HC Wainwright currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.29) per share. HC Wainwright also issued estimates for Esperion Therapeutics’ FY2027 earnings at $0.64 EPS and FY2028 earnings at $0.90 EPS.

ESPR has been the topic of several other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Esperion Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen cut Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, November 1st. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $7.00.

Read Our Latest Analysis on Esperion Therapeutics

Esperion Therapeutics Stock Up 1.8%

Shares of Esperion Therapeutics stock traded up $0.05 during trading on Friday, hitting $2.55. The stock had a trading volume of 2,926,019 shares, compared to its average volume of 5,353,384. Esperion Therapeutics has a 1 year low of $0.69 and a 1 year high of $3.94. The stock has a 50 day simple moving average of $2.70 and a 200 day simple moving average of $1.75. The company has a market capitalization of $513.12 million, a PE ratio of -5.19 and a beta of 0.92.

Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) last released its quarterly earnings results on Thursday, November 6th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.07). The company had revenue of $87.31 million during the quarter, compared to analyst estimates of $78.33 million.

Institutional Investors Weigh In On Esperion Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of ESPR. North Star Investment Management Corp. acquired a new stake in shares of Esperion Therapeutics in the second quarter worth about $25,000. DHJJ Financial Advisors Ltd. boosted its position in shares of Esperion Therapeutics by 209.2% in the third quarter. DHJJ Financial Advisors Ltd. now owns 9,430 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 6,380 shares during the period. Sivia Capital Partners LLC acquired a new stake in shares of Esperion Therapeutics in the second quarter worth $25,000. Meridian Wealth Management LLC acquired a new position in Esperion Therapeutics during the 1st quarter valued at $29,000. Finally, Vanguard Personalized Indexing Management LLC bought a new stake in Esperion Therapeutics in the 3rd quarter valued at $29,000. Institutional investors and hedge funds own 47.39% of the company’s stock.

About Esperion Therapeutics

(Get Free Report)

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.

Further Reading